E. Bargagli (Siena, Italy), A. Wells (London, United Kingdom)
This session is built from abstracts published on the ERS Congress platform from 23 August, in a PowerPoint format with a pre-recorded audio narration. The live session is scheduled from September 5-7 and each presenter will have a 5-minutes live, slide show presentation followed at the end of the session by 30-minutes general discussion.
Defining progression in non-IPF ILD
T. Goos (Leuven, Belgium), L. De Sadeleer (Leuven, Belgium), J. Yserbyt (Leuven, Belgium), E. De Langhe (Leuven, Belgium), A. Dubbeldam (Leuven, Belgium), E. Verbeken (Leuven, Belgium), G. Verleden (Leuven, Belgium), M. Vermant (Leuven, Belgium), J. Verschakelen (Leuven, Belgium), R. Vos (Leuven, Belgium), B. Weynand (Leuven, Belgium), S. Verleden (Leuven, Belgium), W. Wuyts (Leuven, Belgium)
|    |
Automated quantification system predict a progressive phenotype in rheumatoid arthritis-associated interstitial lung disease
J. Oh (Seoul, Republic of Korea), G. Kim (Los Angeles, United States of America), G. Cross (London, United Kingdom), J. Barnett (London, United Kingdom), J. Joseph (London, United Kingdom), J. Song (Seoul, Republic of Korea)
| |
Rheumatoid arthritis-associated interstitial lung disease: time trends
B. Samhouri (Rochester, United States of America), C. Crowson (Rochester, United States of America), S. Achenbach (Rochester, United States of America), V. Kronzer (Rochester, United States of America), J. Davis (Rochester, United States of America), E. Myasoedova (Rochester, United States of America), R. Vassallo (Rochester, United States of America)
| |
Disease behaviour and prognostic factors in Hypersensitivity Pneumonitis with UIP-like pattern
M. Freitas Ferreira Araújo (Braga, Portugal), A. Carvalho (Porto, Portugal), E. Padrão (Braga, Portugal), H. Novais Bastos (Porto, Portugal), N. Melo (Porto, Portugal), P. Mota (Porto, Portugal), A. Morais (Porto, Portugal)
| |
Modified GAP index by including serum KL-6 to assess risk of disease progression in patients with interstitial lung diseases (ILD): preliminary results from the VAMOS study.
F. Bonella (Essen, Germany), M. Vegas Sanchez (Madrid, Spain), P. Millan (Badalona, Spain), E. Gottstein (Essen, Germany), . Sánchez Pernaute (Madrid, Spain), D. Castillo (Barcelona, Spain)
| |
Artificial intelligence-mediated diagnosis of asbestosis
K. Groot Lipman (Amsterdam, Netherlands), C. De Gooijer (Amsterdam, Netherlands), T. Boellaard (Amsterdam, Netherlands), F. Van Der Heijden (Enschede, Netherlands), R. Beets-Tan (Amsterdam, Netherlands), . Bodalal (Amsterdam, Netherlands), S. Trebeschi (Amsterdam, Netherlands), S. Burgers (Amsterdam, Netherlands)
| |
Subclinical ILD is frequent and progresses across different connective tissue diseases
A. Hoffmann-Vold (Oslo, Norway), H. Andersson (Oslo, Norway), S. Reiseter (Oslo, Norway), H. Fretheim (Oslo, Norway), I. Barua (Oslo, Norway), T. Garen (Oslo, Norway), Ø. Midtvedt (Oslo, Norway), R. Gunnarsson (Oslo, Norway), M. Durhem (Oslo, Norway), M. Aaløkken (Oslo, Norway), Ø. Molberg (Oslo, Norway)
| |
Association between monocyte count and ILD progression in subjects with fibrosing ILDs: data from the INBUILD trial
M. Kreuter (Heidelberg, Germany), T. Maher (Los Angeles, California, United States of America), K. Ichikado (Kumamoto, Japan), J. Oldham (Sacramento, California, United States of America), C. Valenzuela (Madrid, Spain), H. Mueller (Biberach, Germany), K. Rohr (Ingelheim am Rhein, Germany), K. Flaherty (Ann Arbor, Michigan, United States of America)
| |
Shifting demographics of patients diagnosed with E-cigarette or vaping associated lung injury (EVALI)
D. Blagev (Salt Lake City, United States of America), S. Callahan (Salt Lake City, United States of America), D. Harris (Salt Lake City, United States of America), D. Collingridge (Salt Lake City, United States of America), M. Lanspa (Salt Lake City, United States of America)
| |
Late Breaking Abstract - A composite serum biomarker index for the diagnosis of systemic sclerosis associated interstitial lung disease: a multicentre, observational, cohort study
A. Jee (Sydney (NSW), Australia), I. Stewart (London, United Kingdom), P. Youssef (Sydney (NSW), Australia), S. Adelstein (Sydney (NSW), Australia), D. Lai (Sydney (NSW), Australia), S. Hua (Sydney (NSW), Australia), W. Stevens (Melbourne (VIC), Australia), S. Proudman (Adelaide (SA), Australia), G. Ngian (Melbourne (VIC), Australia), I. Glaspole (Melbourne (VIC), Australia), Y. Moodley (Perth (WA), Australia), J. Bleasel (Sydney (NSW), Australia), S. Macansh (Sydney (NSW), Australia), M. Nikpour (Melbourne (VIC), Australia), J. Sahhar (Melbourne (VIC), Australia), T. Corte (Sydney (NSW), Australia), .. On Behalf Of The Australian Scleroderma Cohort Study, Australian Scleroderma Interest Group, Australian Idiopathic Pulmonary Fibrosis Registry, And Associated Investigators (Various, Australia)
| |
Discussion
| |